First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH
Status:
Completed
Trial end date:
2021-01-25
Target enrollment:
Participant gender:
Summary
This is a 3-part Phase 1 dose-ranging study to evaluate the safety, tolerability,
pharmacokinetics and pharmacodynamics of single (Part 1) and multiple (Part 2) ascending
doses of BCX9930 in healthy subjects and in subjects with paroxysmal nocturnal hemoglobinuria
(PNH; Part 3). Pharmacokinetics is an analysis of how the body handles the study drug BCX9930
and pharmacodynamics is an analysis of the activity that the study drug BCX9930 may have in
the body.